香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 截至二零二五年十二月三十一日止年度之 年度業績公告 | 財務概要 | | | | | --- | --- | --- | --- | | | 二零二五 年 | 二零二四 年 | 變 動 | | | 人民幣百萬元 | 人民幣百萬元 | | | 收 入 | 1,729.4 | 1,986.7 | (12.9%) | | 毛 利 | 655.6 | 687.4 | (4.6%) | | 毛利率 | 37.9% | 34.6% | | | 淨利潤 | 269.3 | 222.0 | | | 經調整非國際財務報告準則 | | | | | 淨利潤 | 335.3 | 314.6 | | | | 人民幣元 | 人民幣元 | | | 母公司普通權益持有人應佔 | | | | | 每股盈利 | | ...

維亞生物科技控股集團 主席兼首席執行官 毛晨先生 香港，二零二六年三月十八日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 董事會會議日期 維亞生物科技控股 集 團（「本 公 司」）董 事（「董 事」）會（「董 事 會」）謹 此宣佈，本公司 將 於 二 零 二 六 年 三 月 三 十 日（星 期一）舉 行 董 事 會 會 議，藉 以（其 中包括）考 慮及批准 本公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其發佈， 並 考 慮 建 議 派 付 末 期 股 息（如 有）。 承董事會命 於本公告日期，董事會包括三名執行董事，即毛晨 先 生（主 席）、吳 鷹 先 生 及 任 德 林 先生；一名非執行董事，即吳宇挺先生；以及三名獨立非執行董事，即傅磊先生、 李 向 榮 女士及王海光先生。 ...

Summary of the Conference Call for VyaBio Company Overview - VyaBio has become the exclusive CRO partner of NVIDIA in the AI + pharmaceutical sector, leveraging the Complexa model to complete the design of minibinders and validate the effectiveness of its "Lab in the Loop" integrated system [2][3][4]. Core Insights and Arguments - **AIDD Platform Maturity**: The AIDD (AI-Driven Drug Discovery) platform has reached a mature commercialization stage, featuring an in-house algorithm team and a leading position in SBDD (Structure-Based Drug Design), with delivery speed significantly surpassing other partners. Results will be showcased at the 2026 GTC conference [2][3]. - **Positive Business Trends**: The company expects its 2025 performance to meet guidance, with strong growth in China and a recent uptick in overseas inquiries. CDMO (Contract Development and Manufacturing Organization) capacity is nearly saturated, prompting the construction and renovation of three facilities to meet unexpected new orders [2][13][14]. - **Business Model Upgrade**: AI empowerment is driving growth in wet lab services, with exploration into transitioning from traditional CRO service fees to higher-level models like Research Collaboration, utilizing returned funds for AI-driven investment incubation [2][11][15]. - **Cost Advantages**: The existing mature wet lab platform allows AI research without incurring high experimental costs, maintaining industry leadership while planning to increase AI investments [2][16]. Additional Important Content - **Collaboration Background with NVIDIA**: The partnership was disclosed during a presentation at NVIDIA's GTC conference, focusing on using molecular generation models within a "Lab in the Loop" framework to design minibinders. This collaboration has validated both NVIDIA's Complexa model and VyaBio's AIDD capabilities [3][4]. - **Strategic Positioning**: VyaBio is uniquely positioned as the only CRO among NVIDIA's AI + pharmaceutical partners, with a strong internal algorithm team and a systematic approach to integrating AI with wet lab processes, enhancing efficiency and success rates in drug design [6][11]. - **Future Plans and Developments**: The collaboration with NVIDIA is expected to yield more projects, including support for VyaBio's proprietary models in computational acceleration. The "Lab in the Loop" system is crucial for rapid prototyping and validation of drug candidates [4][7][11]. - **Investment Incubation**: The company is actively integrating AI with investment incubation, selectively pursuing projects that leverage AI to enhance efficiency and operational cycles, while maintaining a conservative investment strategy [15][16]. Industry Trends - **CRO and CDMO Business Outlook**: The overall industry trend indicates a strong growth trajectory, particularly in the Chinese market, with a recent increase in overseas inquiries. The company is optimistic about its 2026 business development [12][13]. This summary encapsulates the key points from the conference call, highlighting VyaBio's strategic initiatives, collaborations, and industry positioning.

Core Insights - Viva Biotech is enhancing its AI-driven drug discovery capabilities by optimizing the Proteina-Complexa model to design mini-binders targeting ActRIIA, a receptor important for muscle wasting and lean mass imbalance [1][5] - The collaboration with NVIDIA emphasizes the "Lab-in-the-Loop" workflow, integrating computational design with high throughput protein production and biophysical evaluation to expedite drug discovery [2][4] - The use of AI techniques for sequence selection has led to more efficient mini-binder designs, allowing exploration of new chemical spaces and improving design specificity at reduced costs and time compared to traditional methods [3][4] Company Overview - As a leading contract research organization (CRO), Viva Biotech specializes in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), utilizing computational modeling, generative AI, and extensive wet lab capabilities [4] - The company aims to strengthen its AI algorithm development and enhance its drug discovery processes to deliver high-quality solutions for partners in the evolving AI-driven drug discovery landscape [4]

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong pharmaceutical stocks on March 6, with specific companies showing notable gains [1][2] Group 2 - Zhaoyan New Drug (06127.HK) increased by 3.60% [1] - Weiya Biotechnology (01873.HK) rose by 2.87% [1] - King’s Ray Bio (01548.HK) saw a gain of 1.75% [1]

致：香港交易及結算所有限公司 公司名稱: 维亚生物科技控股集团 (「本公司」) (於開曼群島註冊成立的獲豁免有限公司) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 01873 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 2,129,882,353 0 2,129,882,353 增加 / 減少 (-) 0 0 本月底結存 2,129,882,353 0 2,129,882,353 足夠公眾持股量的確認(註4) 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01873 | 說明 | | | | | | | | | | 法 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

格隆汇2月16日丨维亚生物(01873.HK)宣布，王晖已于2026年2月16日辞任非执行董事职务，即时生效。 ...

Group 1 - The company, Via Biotechnology (01873), announced that Mr. Wang Hui has resigned from his position as a non-executive director, effective immediately on February 16, 2026 [1]

智通财经APP讯，维亚生物(01873)发布公告，王晖先生已于2026年2月16日辞任非执行董事职务，即时 生效。 ...